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Abstract  28 
In the present investigation, it was explored whether food effect on drug absorption in adults is similar 29 
with the food effect after administration of an infant meal with the drug product to adults. After 30 
confirming lack of pharmaceutical and pharmacokinetic interaction, a paracetamol suspension and an 31 
ibuprofen suspension were co-administered to eight healthy adults on a crossover basis in three 32 
different occasions, i.e. in the fasted state (as defined by regulatory agencies, fasted conditions), in the 33 
fed state (as defined by regulatory agencies, fed conditions) and under conditions simulating the fed 34 
state in infants (infant fed conditions). Unlike under fed conditions, under infant fed conditions early 35 
exposure was significantly lower than under fasted conditions for both paracetamol and ibuprofen. 36 
For ibuprofen, Cmax values under infant fed conditions were also significantly higher than under fed 37 
conditions. These data suggest that, even for drugs with non-problematic absorption administered in 38 
simple dosage forms, food effects in infants may not be adequately evaluated if the protocol suggested 39 
by regulatory agencies is applied. The usefulness of the methodology employed in the present 40 
investigation for simulating the fed state in infants deserves further evaluation. Until then, food effects 41 
in infants should be considered cautiously or be evaluated in infants. 42 
 43 
  44 
Introduction 45 
Oral drug delivery is the route of choice for drug administration from birth to adolescence (1–3). 46 
Therefore, understanding drug and drug formulation performance in relation to the prandial 47 
conditions is essential for ensuring safety and efficacy of products to be administered to paediatric 48 
patients, especially newborns (birth – 27 days) and infants (28 days – 2 years) whose diet is specific 49 
(100 % milk in newborns) (4–6).  50 
 51 
Understanding the impact of prandial conditions on drug/drug product performance in paediatric 52 
patients is limited by ethical concerns and the subsequent difficulty to perform such studies. 53 
Difficulties in recruitment are reflected by the limited number of food effect studies in children 54 
published to date [(25 to the best of our knowledge, (7-27)]. Importantly, most of these studies either 55 
do not focus on a specific paediatric subpopulation (9–12,20–28) or focus on school-children (13–56 
15,17). As a result, differences in gastrointestinal physiology across paediatric subpopulations and 57 
differences in meals administered to evaluate the impact of prandial conditions increase data 58 
variability and drastically decrease their usefulness. 59 
 60 
In recent years, there has been a growing interest in investigating whether food effect data collected 61 
in adults are useful for paediatric products (2). Based on a recent draft guidance issued by the U.S. 62 
Food and Drug Administration (FDA), when the same to-be-marketed formulation that is approved for 63 
use in adults is approved for use in a paediatric population, a separate food effect study is not 64 
necessary (6) and the same may also apply in case a paediatric formulation is very similar to the adult 65 
formulation and has been approved based on in vitro dissolution tests (6). To date, nine food effect 66 
studies (7 drugs) in infants and young children have been published (McCracken et al. 1978 (8) – age 67 
range 2-46 months; Ginsburg et al. 1979 (7) – age range 4-45 months). All studies were performed on 68 
a predominantly crossover basis and in all of them the tested product was an antibiotic suspension. 69 
Fasting was defined as no food or milk substance for two hours before and after drug ingestion. The 70 
fed state was induced with milk or infant formula co-administered with the product, i.e. 4 oz of milk 71 
or infant formula administered immediately after drug administration (8) or 4 oz of milk or infant 72 
formula (Similac® or Infamil®) administered with the drug (7). The impact of food on plasma levels 73 
based on these studies is summarised and compared with the impact of food on the plasma levels of 74 
the same antibiotics in adults in Table I. The adult studies were performed with immediate release 75 
products, after overnight fasting (fasting state) and 0-60 min after a solid meal (fed state), on a 76 
crossover basis. Based on the data shown in Table I, only erythromycin ethyl-succinate seems to have 77 
similar food effect in infants and in adults. It should be noted that most of the data presented in Table I 78 
have been collected more than forty years ago. 79 
 80 
Another concern, when food effect data on oral drug absorption in adults are to be extrapolated to 81 
paediatric populations, relates to the design of food effect studies in adults. The recent guideline on 82 
how to conduct food effect studies for newly developed paediatric formulations issued by the FDA 83 
suggests that the food effect for paediatric formulations could be evaluated in adults using foods and 84 
quantities of food that are commonly consumed with drugs in paediatric populations with a 85 
subsequent extrapolation of the results to the paediatric population (6). Although this may be a 86 
practical approach to consider, conceptually, it is different from that applied to date for the evaluation 87 
of food effects on adult pharmaceutical products. In adults, relevant studies aim at detecting the 88 
maximum effect on bioavailability by employing a high-calorie, high-fat meal, with less emphasis on its 89 
exact composition (5,6). Importantly, studies in adults are performed by administering the drug 90 
product 30 minutes after the initiation of consumption of the meal in order to maximise the potential 91 
effect, whereas in paediatric populations drug are usually administered together with meals (19). 92 
 93 
The aim of the present study was to explore whether food effect on drug absorption in adults is similar 94 
with the food effect after administration of an infant meal with the drug product to adults. Specifically, 95 
comparative bioavailability studies of two drugs were performed under three different prandial and 96 
dosing conditions, i.e. 97 
 fasted state conditions as defined by regulatory agencies (fasted conditions) 98 
 fed state conditions as defined by regulatory agencies (fed conditions), and 99 
 simulated infant fed state conditions (infant fed conditions) 100 
Paracetamol (high solubility, weak acid, pka 9.5) and ibuprofen (low solubility, weak acid, pka 4.5) (41–101 
43) were selected as model drugs based on their luminal stability and high intestinal permeability. After 102 
confirming the lack of pharmaceutical interaction and pharmacokinetic interaction, based on available 103 
literature data (44,45), the drugs were co-administered using commercially available paediatric 104 
suspensions, i.e. variations of dosing should impact primarily gastric emptying (paracetamol) or gastric 105 
emptying and, perhaps, dissolution (ibuprofen).  106 
Materials and Methods 107 
 108 
Materials  109 
The commercially available paediatric suspensions Panadol® (24 mg/mL, GlaxoSmithKline Consumer 110 
Healthcare (Ireland) Ltd.) and Nurofen® (20 mg/mL, ReckittBenckiser Healthcare International Ltd.) 111 
were acquired from a local pharmacy. Paracetamol (Ph. Eur.) and ibuprofen (Ph. Eur.) powders were 112 
kindly donated by Uni-Pharma SA (Athens, Greece). Acetonitrile and methanol (Merck, Darmstadt, 113 
Germany) and water (Fischer Scientific, Schwerte, Germany) were of HPLC grade. All other chemicals 114 
were of analytical grade.  115 
 116 
As listed in the patient information leaflet, the Panadol® formulation is composed of the following 117 
excipients: malic acid, azorubine, xanthan gum, maltitol syrup, strawberry flavour L10055, sorbitol 118 
70 % (w/v) (crystallising), sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, 119 
sodium propyl parahydroxybenzoate, sorbitol, anhydrous citric acid, purified water. According to 120 
manufacturer information, the formulation contains 133.3 mg sorbitol (incl. maltitol syrup 121 
content)/mL (46), that is, 5.6 g of sorbitol in the total volume of formulation (42 mL) administered to 122 
the volunteers. This results in a total caloric content of 11.8 kcal for the administered 42 mL Panadol® 123 
suspension. 124 
 125 
The Nurofen® formulation is composed of the following excipients: citric acid, sodium citrate, sodium 126 
chloride, sodium saccharin, domiphen bromide, purified water, polysorbate 80, maltitol liquid, 127 
xanthan gum, strawberry flavor, glycerol. The formulation contains 445.2 mg of maltitol syrup/mL of 128 
formulation (47). According to the Ph. Eur. monograph for maltitol syrup, it is composed of 68-85% 129 
maltitol (w/v) (48), resulting in a range of 12.1 – 15.1 g maltitol for the formulation volume 130 
administered to the volunteers (40 mL). The amount of glycerol in the formulation is 126 mg/mL of 131 
formulation (47), resulting in 5.05 g of glycerol for the formulation volume administered to the 132 
volunteers. Based on these components, the total caloric content of the 40 mL formulation 133 




Study design 138 
This study was a single-dose, open-label, randomised, crossover, three-phase comparative oral 139 
bioavailability study with a washout period of one week. The study was performed in accordance with 140 
the ethical standards for studies in humans of the Declaration of Helsinki and its amendments (49) and 141 
the International Conference on Harmonization Guideline for Good Clinical Practice (50). The study 142 
protocol, informed consent form, and insurance contract received approval by the Executive and Ethics 143 
Committee of the Red Cross Hospital of Athens, Greece (Protocol Nr. 4145/14-02-18). The clinical study 144 
was conducted at the Gastroenterological Department of the Red Cross Hospital of Athens.  145 
 146 
Subjects 147 
Healthy male adults between the age of 20 and 50 years with Body-Mass-Index (BMI) within 20 % 148 
above or below the ideal BMI as determined by the Metropolitan Life Tables were recruited for this 149 
study. Ten healthy adult Caucasian males were recruited. A total of eight volunteers completed all 150 
three study phases. The participation of one volunteer was discontinued, due to inability of consuming 151 
the requested amount of one meal according to the protocol early in the morning. Another volunteer 152 
was unable to proceed with his participation after completing one of the study phases for health 153 
reasons unrelated to the present study. The mean age of the volunteers who completed the three 154 
study phases was 28.4 years (range 21-48 years) and the mean body-mass-index was 23.6 kg/m2 155 
(range 20.3-27.7 kg/m2). No adverse effects were recorded in the present study. 156 
 157 
Inclusion criteria 158 
The health status of the subjects was confirmed by reviewing their medical history and a general 159 
physical examination prior to the study (e.g. blood test to assess electrolyte balance, kidney and liver 160 
function, blood morphologic characteristics, glucose and lipid levels, Hepatitis B surface antigen, 161 
antibodies against Hepatitis C virus, and HIV combined Ag/Ab test). The volunteers had to be able to 162 
abstain from cigarette smoking, alcohol, and over-the-counter and prescription medication(s) for 163 
3 days prior each study phase until the end of the study phase.  164 
 165 
Exclusion criteria 166 
Volunteers were excluded based on the existence of a major health problem (cardiovascular, 167 
pancreatic, hepatic, thyroid etc.), existence of any condition requiring prescription drug therapy, 168 
recent history of gastrointestinal disorder symptoms regardless of the severity (e.g. heartburn, 169 
constipation etc.), swallowing difficulties, and receipt of an investigational agent (new or generic) 170 
within 30 days prior to the initiation of and throughout the study. Further exclusion criteria were the 171 
presence of antibodies indicating active acute or chronic HIV, HBV, or HCV infection in the performed 172 
blood tests. Subjects who could not abstain from use of medication that may affect the gastro-173 
intestinal function (including antacids, PPIs, H2-receptor inhibitors, and laxatives) within 30 days of the 174 
study were excluded.  175 
 176 
Experimental protocol 177 
The volunteers were required to comply with the fasting period of 12 h before the start of each study 178 
day. In the morning of each phase, the subjects arrived at the hospital at 8:00 a.m. and stayed until 179 
completion of the study phase. Upon their arrival, the volunteers’ health status and compliance with 180 
the study protocol was confirmed and water consumption was restricted for the time period of 1h 181 
before and 4.5 h after dosing. A standard lunch comprised of a club sandwich and French fries 182 
(ca. 1000 kcal) was offered 4.5 h after drugs administration. Blood samples (8 mL) were collected from 183 
the forearm vein via peripheral venous catheter prior to drug administration, and 10, 20, 30, 45 min, 184 
1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 h after drugs administration. Upon collection blood was transferred 185 
into EDTA-containing Vacutainers™, following centrifugation and plasma separation. The plasma 186 
samples were divided into two subsamples for separate analysis of ibuprofen and paracetamol to avoid 187 
repeated freeze-thaw cycles and were stored at -20° C. 188 
 189 
Subjects were randomised to receive a single dose of 800 mg ibuprofen (40 mL Nurofen® paediatric 190 
suspension) and a single dose of 1000 mg paracetamol (42 mL Panadol® paediatric suspension) on 191 
three different occasions under three different dosing conditions: administration with water – “fasted 192 
conditions” according to regulatory guidelines for bioavailability/bioequivalence studies (Phase I), 193 
administration with water 30 minutes after the start of a high-fat, high-caloric meal (FDA meal) 194 
consumption – “fed conditions” (Phase II) (5,51), and “infant fed conditions” simulating typical 195 
administration conditions in infants (Phase III). The selected model drugs have shown no relevant 196 
pharmacokinetic interactions when co-administered orally and/or intravenously to healthy humans 197 
(44,45). 198 
 199 
In Phase I the formulations were administered with 168 mL of water (the total fluid volume of the 200 
administered formulations and water was 250 mL) in the following manner: 84 mL of water, 20 mL of 201 
Nurofen®, and 21 mL of Panadol® over 1 minute, followed by 20 mL of Nurofen®, 21 mL Panadol®, and 202 
84 mL of water over 1 minute. The formulations were administered continuously, without time gaps 203 
in-between. Time zero was set just after the completion of the first minute (Figure 1).  204 
 205 
In Phase II, the formulations were administered as described for Phase I but 30 minutes after initiation 206 
of ingestion of the FDA meal [two eggs (Golden Eggs®, Athens, Greece) fried in 31.3 g of butter 207 
(Lurpak®, Danish Dairy Board, Viby, Denmark), two strips of bacon (Nikas®, Athens, Greece), two slices 208 
of toast bread (Karamolegos Α.Ε., Koropi, Greece), 56 g of French fries (Everest, Greece) and 240 mL 209 
of whole cow’s milk (Delta® 3.5% fat, Delta, Athens, Greece)] with a total caloric content of 990 kcal 210 
derived from 25 % carbohydrates, 61 % fats, and 14 % proteins.  211 
 212 
For Phase III, infant formula [Noulac® (Nounou®, Fresland Campina Hellas, Athens, Greece), 213 
47 % carbohydrates, 43 % fats, and 10 % proteins], was selected as an age-representative meal in the 214 
paediatric subpopulations below the age of 24 months based on its frequent use (2). Breastmilk or 215 
infant formula are the exclusive feed until the age of 6 months and remain a main daily feed during 216 
infancy (2). Therefore, infant formula can be considered an appropriate meal for testing food effects 217 
in infants including infants that are being weaned. The volume of infant formula in the present study 218 
was 800 mL (520 kcal) and was based on the recommended infant formula volume for infants, scaled 219 
up by a body surface area factor for adults/infants (2). To simulate dosing conditions in infants during 220 
feeding, the total volume was split into two portions and 400 mL were consumed at a constant rate 221 
over 8 minutes, subsequently 20 mL of Nurofen® and 21 mL of Panadol® were administered over 222 
2 minutes. Upon completion, time zero was set and drugs administration continued by 20 mL of 223 
Nurofen® and 21 mL of Panadol® over 2 minutes, after which the second portion (400 mL) of infant 224 
formula was consumed at a constant rate over 8 minutes. The formulations and infant formula were 225 
administered continuously, without time gaps in-between.  226 
 227 
Both the FDA meal (Phase II) and the infant formula (Phase III) were prepared freshly on each clinical 228 
day. 229 
 230 
Determination of drug plasma levels 231 
Analysis of each drug was performed separately in duplicate. Sample treatment involved plasma 232 
protein precipitation and subsequent centrifugation and drug levels were measured by HPCL-UV based 233 
on previously proposed methods (Lalande et al. 1986; Vertzoni et al. 2003). The chromatographic 234 
system (SpectraSystem®) consisted of a P4000 pump, UV1000 absorbance detector, and an AS3000 235 
autosampler. The above system was controlled by ESIchrome chromatography software package 236 
(v. 3.2, Thermo Fisher Scientific, San Jose, CA USA). 237 
 238 
Paracetamol  239 
For paracetamol analysis, 300 μL trifluoroacetic acid 10 % (v/v) and 150 μL plasma sample were mixed 240 
vigorously for 1 minute. The sample was centrifuged for 10 minutes at 10° C and 10 000 rpm (52). 241 
300 μL of the clear supernatant were collected and diluted with 300 μL water and injected into the 242 
HPLC system. The separation utilised a BDS Hypersil® C18 column (250×4.0 mm, 5 μm) equipped with 243 
a preceding BDS pre-column (10×4.6 mm, 5 μm), with a mobile phase consisting of 10 mM ammonium 244 
formate of pH 6.0 and methanol (90:10 v/v). Paracetamol was eluted at an isocratic flowrate of 245 
0.8 mL/min and detected at 424 nm. Calibration curves using the peak area of paracetamol in spiked 246 
plasma and mobile please showed no significant differences regarding their slope or intercept (t-test, 247 
95% confidence interval). Linearity was shown over the working range 7.5 - 4 000 ng/mL, with a 248 
regression coefficient (R2) of ≥ 0.999. The lower limit of quantification (LLOQ) was 7.5 ng/mL and only 249 
3 out of the 336 samples exhibited drug levels below the LLOQ. Sample quantification was performed 250 
via calibration curves constructed in spiked individual blank plasma from the corresponding volunteer.  251 
 252 
Ibuprofen 253 
For the analysis of ibuprofen, 200 μL plasma sample were acidified by addition of 20 µL of 5 % (v/v) 254 
trifluoroacetic acid, mixed briefly, followed by addition of 380 µL of ice-cold acetonitrile (53). The 255 
mixture was vigorously vortexed for 1 minute and subsequently centrifuged (10 minutes, 10° C, 256 
10 000 rpm). 300 μL of the clear supernatant were collected, diluted with 300 μL mobile phase and 257 
were injected into the HPLC system. Separation was performed with a Fortis® C18 column 258 
(150×3.0 mm, 5 μm) equipped with a preceding BDS pre-column (10×4.6 mm, 5 μm). The mobile phase 259 
consisted of acetonitrile and 100 mM sodium acetate of pH 3.5 (60:40 v/v). Ibuprofen was eluted at an 260 
isocratic flowrate of 0.5 mL/min and detected at 220 nm. Calibration curves employing the peak area 261 
of ibuprofen in spiked plasma and mobile phase showed no significant differences regarding their slope 262 
or intercept (t-test, 95% confidence interval). Linearity was shown over the working range 263 
50 - 10 000 ng/mL, with a regression coefficient (R2) of ≥ 0.999. The LLOQ was 50 ng/mL and all 336 264 
plasma samples exhibited drug levels above the LLOQ. Sample quantification for each volunteer was 265 
performed via calibration curves in spiked individual blank plasma from the corresponding volunteer. 266 
 267 
Data analysis 268 
Concentrations below the LLOQ were assigned a value of 0 μg/mL. The maximum plasma concentration 269 
(Cmax) and the time to reach peak plasma levels (Tmax) were read out directly from raw data. The area 270 
under the plasma concentration-time curve until the last sampling timepoint (AUC0-10h) was calculated 271 
applying the linear trapezoidal rule. The area under the plasma concentration-time curve extrapolated 272 
to infinity (AUC0-inf) was determined with WinNonlin (Version 5.2; Certara USA, Inc., Princeton, USA). 273 
Based on a recent draft FDA guidance, for certain classes of drugs (e.g. analgesic drug products) an 274 
evaluation of the partial exposure could be required to support the determination of the relative 275 
bioavailability of the drug products (FDA, 2019b). In this study, partial AUC values truncated at the 276 
median Tmax of each study phase were calculated applying the linear trapezoidal rule, specifically 277 
AUC0-1.5h, AUC0-3h, and AUC0-4h for paracetamol and AUC0-0.75h, AUC0-1.5h, and AUC0-3h for ibuprofen 278 
corresponding to the median Tmax values in Phases I, II, and III, respectively. Additionally, the partial 279 
AUC0-4h was calculated for ibuprofen, as the absorption phase is assumed to be completed at this 280 
timepoint.  281 
 282 
Comparison between study phases was performed via one-way repeated measures Analysis Of 283 
Variance (ANOVA) tests with a post-hoc Tukey-test, and statistical significance level was set at p < 0.05 284 
after confirming normality and equal variance for the samples under comparison using SigmaPlot 285 
(SigmaPlot 11.0, Systat Software Inc., San Jose, USA). The one-way repeated measures ANOVA was 286 
conducted for AUC0-inf, AUC0-10h, and Cmax for both drugs, the partial AUC0-1.5h, AUC0-2.5h, AUC0-4h for 287 
paracetamol, and the partial AUC0-0.75h, AUC0-1.5h, AUC0-3h, and AUC0-4h for ibuprofen. Friedman repeated 288 
measures ANOVA on Ranks was applied for comparison between Tmax values in the three study phases. 289 




The mean paracetamol plasma concentration-time profiles and the respective 10th and 90th percentiles 294 
are depicted in Figure 2. Under fasted conditions, double peaks in plasma concentration time-profiles 295 
were observed in four subjects in the absorption phase with an evident impact on the mean profile 296 
(Figure 2A). Similar double peak phenomenon could be observed in three subjects under fed 297 
conditions, indicating inconsistent gastric emptying even under fed conditions. Since absorption of 298 
paracetamol is controlled by gastric emptying (55–57), these observations indicate discontinuous 299 
gastric emptying of suspension in some volunteers both in the fasted conditions and in the fed 300 
conditions. The lack of the double-peak phenomenon under infant fed conditions could suggest 301 
different gastric emptying mechanism for the formulation administered with infant formula.  302 
 303 
Paracetamol total exposure (AUC0-10h or AUC0-inf) and Cmax and Tmax values were not significantly 304 
influenced by the prandial and dosing conditions applied in this study (Table II). Based on partial AUC 305 
values, early exposure under fasted conditions and fed conditions demonstrated no significant 306 
difference (Table II), in line with Cmax and Tmax data. However, under infant fed conditions, despite the 307 
lower total caloric content of infant formula (compared with the meal used to induce fed conditions), 308 
absorption of paracetamol was significantly slower than in the fasted state (p<0.05), regardless of the 309 
cut-off time point used for estimating the respective partial AUC (Table II). 310 
 311 
Although there are no published food effect data acquired after administration of paracetamol 312 
suspension, data after administration of 1000 mg immediate-release (IR) paracetamol tablets indicate 313 
that fed conditions do not affect total exposure, while they decrease Cmax and increase Tmax values 314 
(44,58,59). The apparently unaltered Cmax and Tmax values after administration under fed conditions 315 
can be due to the low statistical power (0.049 for Cmax comparison), the different gastric disposition of 316 
a suspension vs. a tablet, and/or the presence of small amount of calories in the administered 317 
suspension.  318 
 319 
Ibuprofen  320 
The mean ibuprofen plasma concentration-time profiles and the respective 10th and 90th percentiles 321 
are depicted in Figure 3. Double peaks were observed in the majority of individuals under fasted 322 
conditions during the absorption phase, which was reflected in the mean plasma concentration-time 323 
profile (Figure 3A). Under fed conditions, double peaks were observed in one subject (for the same 324 
volunteer the phenomenon was also evident for paracetamol), while the occurrence during the 325 
absorption phase was not clear under infant fed conditions. As for the paracetamol suspension, these 326 
observations indicate a discontinuous gastric emptying process of the suspension in some volunteers, 327 
primarily under fasted conditions.  328 
 329 
Ibuprofen total exposure (AUC0-10h or AUC0-inf) appeared not to be significantly influenced by the 330 
prandial and dosing conditions applied in this study (Table III). Differences in Cmax and Tmax values 331 
between fasted conditions and fed conditions or between fasted conditions and infant fed conditions 332 
were not significant. Interestingly, peak exposure (Cmax values) for ibuprofen administration with infant 333 
formula was significantly greater than the observed under fed conditions (Table III). These data could 334 
be related to initial slow absorption rates and a rapid increase at later times (Figure 3C). Drug dosing 335 
under fed conditions significantly reduced early exposure compared to the fasted conditions during 336 
the first 45 min after drug administration (Figure 3B). Early exposure was not significantly changed 337 
when estimated up to longer times. Under infant fed conditions, all partial AUC values, e.g. AUC0-0.75h, 338 
AUC0-1.5h, AUC0-3h, and AUC0-4h, were significantly lower compared to the fasted conditions (Table III). 339 
This observation is in line with the initial slow absorption rates and the increased absorption rates at 340 
later times that could have led to significantly greater Cmax values after infant formula (Table III).  341 
 342 
To the best of our knowledge, there are no published data after administration of ibuprofen 343 
suspensions under fed conditions. Data acquired for the administration of a 600 mg IR tablet suggest 344 
no significant change in total exposure under fed conditions (orange juice included in the meal) (60). 345 
However, total exposure (AUC0-inf) was decreased when ibuprofen IR tablets were administered at a 346 
single dose of 400 mg under fed conditions (orange juice included in the meal) or 800 mg immediately 347 
after a liquid test meal (61,62). It should be noted that in the published studies investigating IR tablets, 348 
deviations from the fed conditions applied in the present investigation (and recommended by 349 
regulators) were evident, e.g. co-administration of orange juice (60,61) and/or drug administration to 350 
intubated volunteers 15 min after initiation of liquid meal consumption (62). Moreover, in these 351 
studies, decreased Cmax and prolonged Tmax values have been reported after ibuprofen dosing under 352 
fed conditions (60–62). As for the paracetamol observations in the present study, the apparently 353 
unaltered Cmax and Tmax values after administration under fed conditions could be caused by the 354 
different gastric disposition of suspension vs. the tablet and/or the presence of small amount of 355 
calories in administered suspension.356 
Discussion  357 
Today, oral paediatric formulation development is usually initiated during clinical Phase II stage of the 358 
adult drug product timelines (3,63). Throughout the pharmaceutical design process for paediatric 359 
formulations paramount emphasis is placed on formulation acceptability and palatability, resulting in 360 
the common utilisation of sweeting agents in an attempt to improve the acceptance of paediatric liquid 361 
formulations for oral administration (4). The present investigation showed that after administration of 362 
paediatric suspension to adults under simulated infant fed conditions, but not under fed conditions, 363 
the absorption of paracetamol and ibuprofen is substantially slower compared with the absorption 364 
under fasted conditions.  365 
 366 
In line with the typical excipients found in paediatric liquid formulations, sweetening agents, i.e. 367 
maltitol syrup and/or sorbitol, can be found among the excipients listed for the two paediatric 368 
suspensions investigated in the present study. Although the polyols included in these formulations 369 
exhibit lower caloric content compared to sucrose, and therefore, the total caloric content of the 370 
formulations is relatively low (ca. 60 kcal for the two formulations), a certain quantity of calories is 371 
inherently and inevitably administered under all studied prandial and dosing conditions.  372 
 373 
The presence of calories in the formulations could raise concerns whether the subjects are in fasted 374 
conditions when these formulations are administered with a glass of water and what might be the 375 
possible implications of the caloric content of the formulations on physiological processes in the 376 
gastrointestinal tract, particularly regarding the regulation of gastrointestinal motility and gastric 377 
emptying. In an investigation performed using a liquid meal containing ca. 400 kcal, the motility phase 378 
in which the test meal was introduced, e.g. during quiescence (Phase I) or during late Phase II 379 
contractions, were found to be the major determinants for the motility response following meal 380 
ingestion and gastric emptying rate (64). Meal administration during late Phase II of the migrating 381 
motility complex (MMC) resulted in Phase III-like duodenal activity shortly after meal administration 382 
accompanied by a biphasic gastric emptying pattern observed for the gastric emptying marker 383 
paracetamol in most of the subjects, whereas meal ingestion during Phase I of the MMC lead to the 384 
typical postprandial Phase II-like motility pattern associated with a monophasic pattern of gastric 385 
emptying (64). Similar observations were reported when 60 kcal of the same liquid study meal were 386 
infused intraduodenally during Phase I or late Phase II, demonstrating that the MMC could influence 387 
postprandial responses and it is not entirely interrupted by nutrient simulation (65). In another study, 388 
Thompson and colleagues reported that the ingestion of glucose solutions (50 g in 200 mL water) 389 
during either MMC Phase I or II did not recognisably alter the appearance of the intestinal motor 390 
pattern (66). Briefly, the quiescence phase continued to persist after glucose ingestion during MMC 391 
Phase I period, while no apparent change of the duodenal irregular motor pattern or occurrence of 392 
MMC Phase III was observed after ingestion of glucose solution during Phase II motor activity (66). The 393 
authors concluded that the insignificant differences between MMC Phase III intervals of the two 394 
timings of ingestion suggested that glucose ingestion would either produce the same delay in Phase III 395 
re-appearance (despite differences in the timing of ingestion) or did not affect the appearance of Phase 396 
III contractions, implying no interference of the glucose solution with the MMC (66). 397 
 398 
Based on the insignificant impact of the caloric load of the suspension formulations, the apparently 399 
discontinuous pattern of the gastric emptying process under fasted conditions could be related to the 400 
variable contractual activity of the gastrointestinal tract and the characteristics of the administered 401 
formulations. The double peak phenomenon could be associated with the viscosity enhancing 402 
excipients in the formulations administered, e.g. xanthan gum. It could be assumed that the 403 
insufficient ability of the suspensions to disperse in the stomach could lead to the emptying of 404 
substantial amounts only under intense contractions. Interestingly, the time interval between these 405 
double peaks, both after administration of paracetamol and ibuprofen in the fasted state, coincided 406 
with the reported cycle of 1.5-2.5 hours for the peristaltic, phasic contractions of the migrating motility 407 
complex (57,67). This possibility is in line with the wide use of paracetamol as a gastric emptying 408 
marker after administration of rapidly disintegrating tablets or solutions (55) and the rare observation 409 
of the double peak phenomenon in relevant previous works (68). 410 
 411 
Under fed conditions, absorption rates did not change significantly from the ones observed under 412 
fasted conditions. This could be attributed either to the power underlying the statistical tests or the 413 
fast transfer of the drugs with the administered water into the small intestine, independently from the 414 
bulk gastric contents under fed conditions, a phenomenon known as “stomach road” or 415 
“Magenstrasse” (69,70). A pathway which may be less easily accessible for IR tablets, possibly due to 416 
the tablet disintegration step required prior to drug dissolution and mixing with the administered 417 
water that would enable the “Magenstrasse” pathway (71,72). 418 
 419 
Perhaps the most interesting observations can be made from the comparison of infant fed vs. the 420 
fasted state data. For both suspensions, unlike to the absorption rates under fed conditions, the 421 
absorption rates under infant fed conditions were significantly slower than under fasted conditions. 422 
Compared to the inhomogeneous viscous meal used for inducing fed conditions, the homogeneous 423 
nature and low viscosity of the infant formula could facilitate mixing between the liquid drug 424 
formulation and infant formula and thus led to the emptying of the drug from the stomach with the 425 
infant meal on a calorie-dependent basis (2). In fact, this slow absorption process led to detection of 426 
significant difference in Cmax values for ibuprofen between fed and infant fed conditions (Table III).  427 
 428 
Finally, from clinical perspective, the onset of pain relief and the timing of peak analgesic effects 429 
following paracetamol or ibuprofen intake profit from a faster rate of absorption. Assuming that the 430 
food type rather than age is the main determinant of gastric emptying (2,73), data from the present 431 
study indicate a substantial delay in paracetamol or ibuprofen absorption and probably subsequent 432 
delayed induction of pharmacodynamic effects when a suspension is administered during feed with 433 
breastmilk or infant formula in infants.  434 
Concluding remarks 435 
The present exploratory study in healthy adults suggests that even for drugs with non-problematic 436 
absorption (no intestinal permeability limitations, highly soluble in the small intestine, no documented 437 
intraluminal interactions with food components) administered in simple dosage forms (aqueous 438 
suspensions), food effects on drug absorption in infants may not be adequately evaluated by data 439 
collected as suggested by regulatory agencies for adult drug products. It would be highly interesting to 440 
evaluate the extent to which differences between fasted conditions and infant fed conditions in adults 441 
reflect differences between fasted state conditions and fed state conditions in infants. Until then, for 442 
any drug product, food effects in infants should be considered cautiously or be evaluated in infants.443 
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Table I Published food effect data for seven antibiotic suspensions. 656 
Drug 








































































































































a Cmax, AUC0-6 (µg/mL∙h), and Tmax values from the mean plasma profiles were published in studies in 657 
infants 658 

































































































































Table II Mean ± SD values of pharmacokinetic parameters for paracetamol in each phase of the clinical 660 







Infant fed conditions 
AUC0-inf (μg/mL×h) 39.4 ± 9.7 40.4 ± 11.0 39.2 ± 10.1 
AUC0-10h (μg/mL×h) 35.8 ± 7.9 35.5 ± 8.9 34.0 ± 8.0 
Cmax (μg/mL) 7.85 ± 1.54 6.96 ± 2.42 7.24 ± 1.32 
Tmax (h) 1.5 (0.33 - 4) a 2.5 (1.0 - 5) a 4 (1.5 - 5) a 
AUC0-1.5h (μg/mL×h) 6.78 ± 3.14 5.27 ± 2.99 2.12 ± 1.37 b 
AUC0-2.5h (μg/mL×h) 12.7 ± 4.4 10.5 ± 4.8 5.81 ± 2.72 b 
AUC0-4h (μg/mL×h) 21.4 ± 5.2 18.5 ± 5.9 13.7 ± 4.3 b 
a median value (range) 662 
b significantly different from Phase I 663 
 664 
  665 
Table III Mean ± SD values of pharmacokinetic parameters for ibuprofen in each phase of the clinical 666 







Infant fed conditions 
AUC0-inf (μg/mL×h) 205 ± 60 203 ± 47 213 ± 54 
AUC0-10h (μg/mL×h) 192 ± 50 185 ± 40 194 ± 44 
Cmax (μg/mL) 45.0 ± 7.4 41.3 ± 10.6 49.6 ± 9.0 c 
Tmax (h) 0.75 (0.33 – 4) a 1.5 (1.0 – 3) a 3.3 (0.33 – 5) a 
AUC0-0.75h (μg/mL×h) 19.4 ± 8.2 10.8 ± 6.5 b 7.7 ± 9.0 b 
AUC0-1.5h (μg/mL×h) 46.7 ± 15.6 32.6 ± 19.6 18.6 ± 17.4 b 
AUC0-3h (μg/mL×h) 96.9 ± 21.0 80.5 ± 34.4 52.6 ± 29.2 b 
AUC0-4h (μg/mL×h) 126 ± 25 109 ± 36 85.2 ± 29.4 b 
a median value (range) 668 
b significantly different from Phase I 669 
c significantly different from Phase II 670 
 671 
 672 
  673 
Figure Captions 674 
Figure 1 Graphical depiction of the times of meals vs. drug products administrations in the present 675 
clinical study: Phase I, fasted conditions; Phase II, fed conditions; Phase III, infant fed condtions.  676 
Figure 2 Mean plasma paracetamol concentration-time profiles following co-administration of 1000 677 
mg paracetamol suspension and 800 mg ibuprofen suspension to healthy male adults (n=8) under 678 
different prandial and dosing conditions: (A) fasted conditions, (B) fed conditions, (C) infant fed 679 
conditions. The shaded area represents the 10th and 90th percentiles estimated from the experimental 680 
data points.  681 
Figure 3 Mean plasma ibuprofen concentration-time profiles following co-administration of 1000 mg 682 
paracetamol suspension and 800 mg ibuprofen suspension to healthy male adults (n=8) under 683 
different prandial and dosing conditions: (A) fasted conditions, (B) fed conditions, (C) infant fed 684 
conditions. The shaded area represents the 10th and 90th percentiles estimated from the experimental 685 
data points.  686 
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